We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00606476
Recruitment Status : Terminated
First Posted : February 4, 2008
Last Update Posted : November 25, 2013
Information provided by (Responsible Party):
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : September 2012
  Study Completion Date : September 2012
  Certification or Request for Extension to Delay Results Submission: October 30, 2013